Sphera Funds Management’s Axsome Therapeutics AXSM Stock Holding History

Sphera Funds Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-301,000	Closed	-$1.69M	–	113
2017 Q4	$1.69M	Sell	301,000 -200,000	-40%	-$1.01M	0.2%	106
2017 Q3	$2.78M	Hold	501,000	–	–	0.4%	65
2017 Q2	$2.76M	Buy	501,000 +100,000	+25%	+$419K	0.47%	67
2017 Q1	$1.56M	Buy	+401,000	New	+$1.92M	0.31%	80
2016 Q2	–	Sell	-109,069	Closed	-$938K	–	97
2016 Q1	$938K	Sell	109,069 -110,931	-50%	-$1.02M	0.2%	82
2015 Q4	$2.01M	Buy	+220,000	New	+$1.94M	0.29%	86

Other funds holding AXSM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Sphera Funds Management's AXSM Position: Q1 2018 in Review

Sphera Funds Management sold out of Axsome Therapeutics (AXSM) in Q1 2018, closing a stake of 301,000 shares — an estimated $1.69M sold.

Sphera Funds Management first reported a position in AXSM in Q4 2015 and held it in 6 quarters. The position peaked at $2.78M in Q3 2017. 36 funds tracked by Wall St. Rank hold AXSM as of Q1 2018.

Sphera Funds Management reported no remaining Axsome Therapeutics position as of Q1 2018 after selling out during the quarter.
Sphera Funds Management sold 301,000 Axsome Therapeutics shares in Q1 2018, an estimated $1.69M.
Sphera Funds Management first reported a position in Axsome Therapeutics in Q4 2015 and held it in 6 quarters.
Sphera Funds Management's Axsome Therapeutics position peaked at $2.78M in Q3 2017.
36 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2018.

Based on Sphera Funds Management's 13F filing for Q1 2018, filed 10 May 2018.